Cryopreservation Excipient for Cell Therapies

AMSBIO has launched STEM-CELLBANKER® EX - a next generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.

Cryopreserved sample held with tweezers. Image credit: AMS Bio

Rapid developments in cell, tissue, and gene therapies over the last decade have redefined what a cell therapy can be. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. However, the development of a cell therapy using a process that includes the washing out of the cryopreservation solution is not only inconvenient but can result in loss of cells and lower cell viability. Due to its unique formulation, STEM-CELLBANKER® EX eliminates the need for this step.

Assisting easier implementation in a clinical environment - STEM-CELLBANKER® EX is a chemically defined cryopreservation media solution that only includes components registered as inactive ingredients that have already been approved for intravenous administration. Manufactured under strict US, EU and PIC/S GMP guidelines - STEM-CELLBANKER® EX is a serum free and animal component free, sterile DMSO-containing solution optimized for cryopreserving human cells, tissues and organoids.

Proven to maintain cell pluripotency, normal karyotype, and proliferation ability post-thaw - STEM-CELLBANKER® EX delivers consistently higher cell viability and cell recovery than other cryopreservation media.

For further information please visit https://www.amsbio.com/stem-cell-cryopreservation-ex/  or contact AMSBIO on+44-1235-828200 / +1-617-945-5033 / [email protected]

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2021, November 05). Cryopreservation Excipient for Cell Therapies. AZoLifeSciences. Retrieved on January 22, 2022 from https://www.azolifesciences.com/news/20210910/Cryopreservation-Excipient-for-Cell-Therapies.aspx.

  • MLA

    AMS Biotechnology. "Cryopreservation Excipient for Cell Therapies". AZoLifeSciences. 22 January 2022. <https://www.azolifesciences.com/news/20210910/Cryopreservation-Excipient-for-Cell-Therapies.aspx>.

  • Chicago

    AMS Biotechnology. "Cryopreservation Excipient for Cell Therapies". AZoLifeSciences. https://www.azolifesciences.com/news/20210910/Cryopreservation-Excipient-for-Cell-Therapies.aspx. (accessed January 22, 2022).

  • Harvard

    AMS Biotechnology. 2021. Cryopreservation Excipient for Cell Therapies. AZoLifeSciences, viewed 22 January 2022, https://www.azolifesciences.com/news/20210910/Cryopreservation-Excipient-for-Cell-Therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
You might also like... ×
Latest tools for COVID-19 Omicron variant research